



सत्यमेव जयते



क.रा.बी.नि.
ESIC

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

DG-ESIC CENTRAL RATE CONTRACT NO. – 168
FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 11th DECEMBER, 2025 to 10th DECEMBER, 2027)

HORMONES
DRUGS USED IN INFECTION AND INFESTATION
ANAESTHETIC AND AGENTS FOR PRE-MEDICATION
FLUIDS AND ELECTROLYTES

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Room No. 312 & 321, 3rd Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎ 011-23604773, ✉ dmc-rc@esic.gov.in



क.स.बी.नि.
ESIC

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 168	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 168	13-17
3.	Indexing of approved Items	18-22
4.	Rate Schedule of Rate Contract No. 168	23-35

क.स.बी.नि.
ESIC



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in
☎011-23604773, ✉ dmc-rc@esic.gov.in

No. U-25/12/165 to 169/2024-Medical.V (E-754406)/168 (RC-168)

Dated: 12.12.2025

From:

The Director General,
E.S.I. Corporation,
Panchdeep Bhawan,
C.I.G Road,
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges
Medical Superintendent – All ESIC & ESIS Hospitals,
Director, ESI Scheme – All States & UTs.

Sub: **PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 168 EFFECTIVE FROM 11.12.2025 TO 10.12.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

Validity of this Rate Contract is for a period of two years i.e. w.e.f. 11.12.2025 TO 10.12.2027.

Further, the following terms & conditions are issued to govern operation of the Rate Contract:

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorized and included in the list of DDOs. **DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.**
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

PROFORMA FOR NON-SUPPLY REPORT

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

SUPPLIES

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved** Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking/Labelling:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) **It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.**
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time (Where ever Applicable).



20. Life Period :

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

21. Pharmacopoeia Specifications:

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards (Where ever Applicable).

24. Testing of Drugs – Quality Control

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -

A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-

If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
- **100% Forfeiture of Performance Security** from the respective DGEISIC Rate Contract for all the quoted drugs.



- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs):

1. If single item/ Batch of item is declared NSQ under Category B:

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3rd onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**



- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
 - Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
 - **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.**
 - Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
 - Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C. CATEGORY ' C ' DEFECT (Minor Defects)

1.If single item/ Batch of item is declared NSQ under Category C

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

- a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.**
 - Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
 - Warning to be issued to the firm for the NSQ item.
 - Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.**



- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- **Any subsequent (2nd NSQ onwards) NSQ** reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The**



extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.

ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.

- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
 - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.
30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -



(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.


(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1st Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order. Same principal applies to L2 Firm(in case order is required to be placed with L2).

31. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years along with forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.
32. The Letter of Award issued to the firms by this office cannot be used for placing orders.
33. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.
34. Force Majeure:
If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.
35. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.
36. All Deans/MSs/DIMS/Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs(strictly monitor Re-Order Level, Buffer Stock, Lead Time etc.) in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.

This issue with the approval of Competent Authority.


Yours faithfully,

Encl.: As above.


(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Services/ Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.


(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विद्वान् आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(मु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.J G Road, New Delhi-02

क.रा.बी.नि.
ESIC



List of Approved Pharmaceutical firms of Rate Contract No. 168

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
1.	168	Aculife Healthcare Pvt. Ltd.	Commerce House V, Besides Vodafone House, Prahalad Nagar Corporate Road, Ahmedabad-380051	079-26839100, 079-26839108, 9099165218, brijeshsanghvi@aculife.co.in , nitantbhatt@aculife.co.in
2.	168	ALPA LABORATORIES LTD	33/2, A.B. Road, Pigdamber 453 446, Indore (MP)	0731 4294567, 7415794617, tenders@alpalabs.in
3.	168	Bal Pharma Ltd	Bal Pharma Ltd, 5th Floor, Lakshminarayan Complex, Palace Road, Bangalore	080-41379527, 080-22354057, 9480811168, rajesh@balpharma.com , institutionalsales@balpharma.com
4.	168	BDR Pharmaceuticals International Private Limited	Registered office at : 407/408, Sharda Chambers, 15 New Marine Lines, Mumbai 400020 (Maharashtra) Admn. : Engineering Centre, 6th Floor, 9 Matthew Road, Opera House, Charni Road. Mumbai - 400004	022-40560560, 022-40560555, +91-9811383631; +91-9136003333, manoj.kapoor@bdrpharma.com , tender@bdrpharma.com
5.	168	Bharat Serums And Vaccines Limited	3rd floor, Liberty Towers, Plot No. K-10, Behind Reliable Plaza, Kalwa Industrial Estate, Airoli, Navi Mumbai - 400708	022-45043456, 022-45043200, 9967657228, institution@bsvgroup.com , nitin.nagar@bsvgroup.com
6.	168	Biocon Biologics Limited	Biocon House, Tower-3, Smicon Park, Electronic City, Phase 2, Bengaluru - 560100	080 67751329, 080 67751320, 9820407013, marketaccess.bbl@biocon.com
7.	168	Biodeal Pharmaceuticals Ltd.	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Himachal Pradesh 174101	0120-6025048, 0120-6025048, 7428744221, institution1@biodealpharma.com , institution@biodealpharma.com
8.	168	Cipla Ltd.	Cipla House Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013	022 24826000, 022 24826120, +91 9820273567 +91 9506692389, Institution@Cipla.com , vishwas.ahuja@cipla.com , prashant.gupta1@cipla.com , praveen.kumar18@cipla.com
9.	168	Dr. Reddy's Laboratories Limited	7-1-27, Ameerpet, Hyderabad-500016, Telangana, India.	040-49048400, 040-49048800, 91 9000995868 & 91 9154302501, ibtpricing@drreddys.com , ibt@drreddys.com



List of Approved Pharmaceutical firms of Rate Contract No. 168

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
10.	168	FRESENIUS KABI INDIA PRIVATE LIMITED	Ninth Floor, AP 81, S No 83, North Main Road, Near Hard Rock Cafe, Mundhwa, Pune 411036, Maharashtra, India. Tel: +91 20 67649000	020 67649000, 020 26634710, 9049275533, jatish.kumar@fresenius-kabi.com, instkabi@fresenius-kabi.com, Mohammad.alim@fresenius-kabi.com, instkabi@fresenius-kabi.com
11.	168	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Limited, Glenmark House, B.D.Sawant Marg, Chakala, Andheri East, Mumbai - 400099	022-40189999, 022-40189986, 9867027126, govt.tenders@glenmarkpharma.com
12.	168	HAB Pharmaceuticals & Research Ltd	A-301 PENINSULA BUSINESS PARK, GANPATRAO KADAM MARG LOWER PAREL MUMBAI 400013	022-66261409, 022-66261414, 9930212908, marketing@habpharma.in, institution@habpharma.in
13.	168	Hindustan Laboratories Limited	A-302, Victory Park, Chandavarkar Road, Borivali (West), Mumbai - 400092, Maharashtra	022-42460500, 42460526, 022-42460531, 7710055194, sales@hindlab.com, tender@hindlab.com, kunjaldedhia@hindlab.com
14.	168	Indoco Remedies Ltd.	Indoco Remedies Limited, Indoco House, 166, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.	022 - 6287 1000/ 6817 1250, 022 - 2652 0884, 9004046733, mshetty@indoco.com, kiran.borle@indoco.com
15.	168	MAAN PHARMACEUTICALS LTD.	MAAN PHARMACEUTICALS LTD., PLOT NO.1, G.I.D.C PHASE-2, MODHERA ROAD, MEHSANA-384 002	02762-224642, 02762 224610, 9825070124, info@maanpharma.com
16.	168	Macleods Pharmaceuticals Limited	Atlanta Arcade, Marol Church Road, Opposite Leela Hotel , Andheri (East), Mumbai - 400059	2266762672, 2229256599, 7304564056, tenders@macleodspharma.com
17.	168	MANKIND PHARMA LIMITED	M/s. Mankind Pharma Limited, 208, Okhla Industrial Estate, Phase-3, New Delhi-110020	011-46541400, 011-46541382, 9599911736 , 9873661749, tender@mankindpharma.com, rajesh.kaul@mankindpharma.com, gaurav.saxena@mankindpharma.com
18.	168	MASCOT HEALTH SERIES PVT LTD	B-1/635, 2nd Floor, Near Janakpuri East Metro Station, Janakpuri, New Delhi 110058	011-28542407/08/10, 8800220714, gmsales.mkt@mascothealth.com, rk.mascothealth@gmail.com





ए. ए. सी. ई.
E S I C

List of Approved Pharmaceutical firms of Rate Contract No. 168

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
19.	168	Merck Specialities Private Limited	Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079	022 62109000, 022 62109999, 9899689294, nitesh.sharma@merckgroup.com, trendpro@merckgroup.com
20.	168	MESMER PHARMACEUTICALS	Mesmer Pharmaceuticals, Vedha No 13, Mangala Nagar, 1st Main Road, Porur, Chennai-600116, Tamil Nadu.	044-22522618, 9444903427, tenders.mesmer@iconlife.in, gvsm ani.mesmer@iconlife.in
21.	168	MICRO LABS LTD	No. 31, Race Course Road, Bangalore-560 001	: +91-80-2237 0451-57 line: +91-80-2237 0463 , 9350808984 ; 9591211411, rakeshsharma_micro@yahoo.co.in
22.	168	MICRON PHARMACEUTICALS	Plot No. 2117, A-2, Phase III GIDC Vapi 396 195	0260 2405400/405/407/412, 0260 2405419, 9924170750, sales@micronpharma.in, contactus@micronpharma.in, sales@micronpharma.in
23.	168	Morepen Laboratories Limited	2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana)	0124 - 4892000, 0124 - 4892000, 9891759817, yadvinder.singh@morepen.com, institution@morepen.com
24.	168	Naprod Life Sciences Pvt. Ltd.	304, Town Center, Andheri Kurla Road, Andheri East, Mumbai- 400059	022 4093 9000, +91 8100644440, abhijit.mukherjee@naprodgroup.com, institution@naprodgroup.com
25.	168	Novo Nordisk India Private limited	NXT-2, 1 & 2nd Floor, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore - 560045	8040303200, 8041123518, 9934300408, institutionsales@novonordisk.com, surj@novonordisk.com
26.	168	Overseas Health Care Private Limited	M/s. OVERSEAS HEALTHCARE PRIVATE LIMITED, 335KM Milestone, National Highway No.1, P.O. Box 25, Phillaur, District Jalandhar, Punjab State	01826-222886, 01826-222885, 9872019733, info@overseashealthcare.co.in, dm ohcpl@gmail.com
27.	168	Pfizer Products India Private Limited	The Capital 1802/1901, Plot No C-70, G-Block, Bandra Kurla Complex, Bandra (E) Mumbai 400051	02266932000, 02226540274, 9771414156, governmenttendersppi@pfizer.com, Satendra.seth@pfizer.com, Raje sh.kadian2@pfizer.com, vijay.pangl e@pfizer.com





List of Approved Pharmaceutical firms of Rate Contract No. 168

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
28.	168	Primus Pharmaceuticals	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour ,173030, H.P	9034004055 and 7056797055, tenders@primuspharmaceutical.com,marketing@primuspharmaceutical.com
29.	168	Pulse Pharmaceuticals Pvt Ltd	Pulse Pharmaceuticals Pvt Ltd., Plot No: 18/1, Sector III, HUDA Techno Enclave, Hitech City, Hyderabad - 500 081.	91-40-23119992, 91-40-23119992, 9346155755, 9311083087, suresh@pulsepharma.net,dineshkuumar@pulsepharma.net
30.	168	Reliance Life Sciences Pvt. Ltd.	R-282 , TTC Area of MIDC, Thane Belapur Road, Navi Mumbai-400701	,+91-22-35338000, ,+91-2235338099, 8591404088, mahesh.kumar@relbio.com
31.	168	RIVPRA FORMULATION PVT. LTD,	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)	(0120-4277177), 0120-4277177, 9999811834, 8800394441, tender@rivpraformulation.com,info@rivpraformulation.com
32.	168	Servier India Private Limited	1703, 17th Floor, Crescenzo Business District, 'B' Wing, Plot Nos. C 38 & 39, "G" Block, Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai – 400051.	022 – 68100700, servier.sales@servier.com,m.gurulingam@servier.com
33.	168	Signature Phytochemical Industries	Signature Phytochemical Industries, A-301 Peninsula Business Park Ganpatrao Kadam Marg Lower parel Mumbai 400013	022-66261400, 022-6624141, 8976716569, marketing@signaturepi.in
34.	168	T.Walker's Pharmaceuticals Pvt Ltd	Gat No 285- A Plot No 10 +11 Village Kasaramboli At post Ambedvet Tal Mulshi Dist. Pune Maharashtra Pin:412108	9371009400, 9822675123, t.walkers1916@gmail.com,abhijee t.kudalkar@twalkerspharma.com
35.	168	Tablets (India) Limited	# 72, Marshalls Road, " Jhaver Centre" R A Building, 4th Floor, Egmore, Chennai, 600 008	044 - 4205 0000, 044 - 2858 9090, hd@tabletsindia.com
36.	168	Theon Pharmaceuticals Limited	Plot no. 400, Industrial Area, Phase-1, Panchkula-134113	0172-5210200, 0172-5033851, 7696000688, tender@theonpharma.com,spsing h@theonpharma.com



List of Approved Pharmaceutical firms of Rate Contract No. 168

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
37.	168	Torrent Pharmaceuticals Ltd,Ahmedabad	Torrent Pharmaceuticals LTD, Torrent House, Off Ashram Road, Ahmedabad-380009	079 26599551, 079 26582100, 7069000550 , 578 , 509 , 559, hemantameher@torrentpharma.com,vikrampatel@torrentpharma.com,jaydabhi@torrentpharma.com,bijendrakumarsharma@torrentian.com,hadmatkhatik@torrentpharma.com,ISDORDERS@TorrentPharma.com
38.	168	UNICURE INDIA LTD	C-21, 22 & 23, Sector-3, Noida-201301, distt. Gautam Budh Nagar (U.P.)	0120-4786713, 0120-4320184, 9810337912, unicare@unicureindia.com,mkumar712@gmail.com
39.	168	Windlas Biotech Limited	705-706, Vatika Professional point, sector-66 golf course ext, road, Gurgaon-122001 Haryana	124-2821030, 124-2821060, 9555823672, institutionalhead@windlasbiotech.com
40.	168	Wings Biotech LLP	J-13, Udyog Nagar Industrial Area, Near Peeragarhi Metro Station, Delhi- 110041	011-45922222, 9871112877, manager.govtupply@wingsbiotech.com,institution.exe@wingsbiotech.com,wingstender.co@gmail.com
41.	168	Zuventus Healthcare Limited	Zuventus House, Plot Y2, CTS NO: 358/A2, Near Nahur Railway Station, Nahur (West), Mumbai- 400078	022 35060000, 022 20812898, 9054797511, Rajiv.Kumar@zuventus.com,sheetal.khanvilkar@zuventus.com
42.	168	Zydus Healthcare Limited	M/s. Zydus Healthcare Limited Zydus Tower, CTS No. 460/6, Village Pahadi, Opposite IB Patel Road, Goregaon E, Mumbai – 400063	91-22-62721700, 91-22-62721700, 9957194623, institutionsales@zyduslife.com
43.	168	Zydus Lifesciences Limited	Zydus Lifesciences Limited 4th Floor, "B" Wing, 'Zydus Corporate Park', Scheme No. 63, Survey No. 536,Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G.Highway, Ahmedabad - 382 481, Gujarat, India.	+91-079-71800000, 91-079-48040000, +91-079-71800192, +91-91-98723 14125, ZLL_Institution_Business@zyduslife.com,NishuS.Dubey@zyduslife.com

भारतीय
ESIC

Index RC- 168

S.No.	RC No.	Item No.	Item Name and Description
1	168	134	Prednisolone Tab/Cap-Each Tab/Cap to contain Prednisolone 5 mg.
2	168	137	Acarbose Tab/Cap-Each Tab/Cap to contain: Acarbose 50 mg
3	168	172	Erythromycin Oral Susp-Each 5ml to contain: Erythromycin 125mg, 30ml Bottle
4	168	202	Diethyl Carbamazine Syp-Each 5ml to contain: Diethyl Carbamazine Citrate 120mg., 100ml Bottle
5	168	251	Lignocaine Inj-Each vial to contain: Lignocaine Hcl 2%w/v., 30ml Vial
6	168	277	Sterile Water For Inj-Each Amp to contain: Sterile Water For Injection,5ml Amp
7	168	426	Neostigmine Inj- Each ml to contain: Neostigmine 0.5mg,1ml Amp
8	168	447	Rocuronium Inj- Each ml to contain: Rocuronium 10mg.,5ml Vial/Amp
9	168	479	Prednisolone Tab/Cap- Each Tab/Cap to contain: Prednisolone 10 mg
10	168	1164	Hydrocortisone Sod. Succinate Inj-Each vial to contain: Hydrocortisone Sod. Succinatee qv. to Hydrocortisone 100 mg
11	168	1173	Human Insulin Biphasic Mixed (30% + 70%)Each vial to contain: Human Insulin Biphasic 30% Soluble + 70% NPH 40 units / ml.,10ml Vial
12	168	1318	Glycine Soln-Each Bottle/Bag to contain: Glycine 1.5% (1.5 gm /Glycine 1.5% (1.5 gm / 100 ml),3Ltr Bottle/Bag
13	168	1322	Amino Acid (For IV Infusion)- Each ml to contain: L-Arginine Hcl 8.0 mg, L-Histidine Hcl. 4.0mg, L-Isoleucine 5.5mg, L- Lysine Hcl. 22.3mg, L-Methionine 7.1mg, L-Threonine 5.4mg, L-Phenylalanine 8.7mg, L- Leucine 12.3 mg, L-Valine 6.1 mg, Glycine 10.0mg, L-Tryptophan 1.8mg,Sorbitol 50.0 mg.,200ml Glass Bottle
14	168	1326	SODIUM BI CARBONATE INJECTION IP 10.0 ML AMPOULE SODIUM BI CARBONATE IP (75 mg/ml) WATER FOR INJECTION IP (Q. S. TO 1.0 ml)
15	168	1389	Mannitol + Glycerin Infusion- Each Bottle to contain: Mannitol I.P. 10%, Glycerin I.P. 10%,100ml Bottle



ए. ए. सी. ई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
16	168	1484	Imipenem + Cilastatin Inj-Each vial to contain: Imipenem 500mg, Cilastatin 500mg
17	168	1550	Linezolid Tab/Cap-Each Tab/Cap to contain: Linezolid 600mg
18	168	1559	Linezolid Inj-Each Vial/bag to contain: Linezolid 600mg
19	168	1591	Saxagliptin Tab/Cap - Each Tab/Cap to contain: Saxagliptin 2.5mg
20	168	1700	Ivermectin Tab/Cap - Each Tab/Cap to contain: Ivermectin 6mg
21	168	1765	Voglibose Tab/Cap - Each Tab/Cap to contain: Voglibose 0.2 mg
22	168	1771	Clindamycin Tab/Cap- Each Tab/Cap to contain: Clindamycin 300mg
23	168	1772	Clindamycin Inj- Each Vial to contain: Clindamycin 600 mg ,4ml Amp
24	168	1779	Interferon Beta 1-A Inj- Each PFS/PFP to contain: Interferon beta 1-a 30 mcg (6 million IU).
25	168	1838	GarenoxacinTab/Cap- Each film coated Tab/Cap to contains:Garenoxacin Mesylate equivalent to Garenoxacin 200mg exceipients qs
26	168	1894	Saxagliptin & Metformin(ER) Tab/Cap- Each film coated Tab/Cap to contain:Saxagliptin 5 mg + Metformin Hcl 500mg (ER)
27	168	1896	Linagliptin Tab/Cap- Each film coated Tab/Cap to contain: Linagliptin 5mg
28	168	1902	Cefixime And Pre&Probiotic Tab/Cap-Each Tab/cap. to contain: Cefixime IP as Trihydrate equivalent to Anhydrous Cefixime 200 mg and Each Inner cap to contain: Sterptococcus Faecalis T-110 JPC 60million Clostridium Butyricum TO-A 4 million Bacillus MesentericusTO-AJPC 2 million Lactic Acid Bacillus 100million
29	168	2034	Teneligiptin 20mg Tab/Cap- Each Tab/Cap to contain: Teneligiptin 20mg
30	168	2236	Metformin ER Tab/Cap- Each uncoated Extended Release Tab/Cap contains: Metformin 1000 mg.
31	168	2241	Valacyclovir Tab/Cap- Each Film Coated Tab/Cap Contains: Valacyclovir Hydrochloride

क.स.सी.ए.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			USP Equivalent To Valacyclovir 500 Mg
32	168	2347	Heparin Oint/Cream- Each gm to contain: Heparin Sodium 50 IU, Benzyl Nicotinate 2mg,20gm Tube
33	168	2356	Ofloxacin, Sodium Chloride Soln- Each 100ml to contain: Ofloxacin IP 200mg, Sodium Chloride 900mg ,100ml Bottle
34	168	2363	Normal Saline- Each Bottle/Bag to contain : Normal Saline 0.9%,3 Litre Bottle/Bag
35	168	2377	Atropine Inj- Each ml to contain: Atropine 0.6 mg,1ml Vial/Amp
36	168	2381	Darbepoetin Inj- Each PFS to contain: Darbepoetin Alfa 60mcg
37	168	2384	Remogliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Remogliflozin Etabonate 100mg, Excipients Q.S.
38	168	2385	Mefipristone + Misoprostol- Each Kit to contain:Mefipristone 200mg (01 Tab/Cap), Misoprostol 200 mcg (04 Tab/Cap)
39	168	2396	Dinoprostone Gel- Each Tube to contain: Dinoprostone 0.5mg,3gm Tube
40	168	2461	Cefpodoxime+Prebiotic Tab/Cap-Each Tab/ Hard Cellulose Cap contains:Cefpodoxime Proxetil IP equivalent to Cefpodoxime 200mg Each inner Tab/ Hard cellulose Cap contains:Streptococcus faecalis T-110 JPC 60 Million, Clostridium butyricum TO-A 4 Million, Bacillus mesentericus TO-A JPC 2 Million, Lactic acid bacillus 100 Million (Lactobacillus sporogenes)
41	168	2464	Artemether 80mg+Lumefantrine 480mg Inj/ Dispersible Tab/Cap- 80mg+Lumefantrine 480mg
42	168	2465	Normal Saline/ Sodium Chloride Soln-Each Bottle to contain: Normal Saline/ Sodium Chloride 0.45% IV,500ml Bottle
43	168	2466	Normal Saline/ Sodium Chloride Soln-Each Bottle to contain: Normal Saline/ Sodium Chloride 0.9%,100ml Bottle
44	168	2468	Insulin Human Regular/ Soluble/ Actrapid- Each Vial/Amp to contain: Insulin Human Regular/ Soluble/ Actrapid 40IU/ML,10ml Vial/Amp
45	168	2700	Alogliptin Tab/Cap: Each tab/cap to contain Alogliptin 25mg



ए. ए. सी. ई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
46	168	2701	Alogliptin + Metformin Tab/Cap:Each Tab/Cap to contain Alogliptin 12.5mg + Metformin 500mg Tab/Cap
47	168	2702	Amoxicillin+ Clavulanic Acid Drop: Each ml to contain Amoxicillin 80 mg, Clavulanic Acid 11.4 mg , Pack of 10 to 15 ml
48	168	2704	Balanced Salt Solution- 500ml.
49	168	2706	Cefepime injection: Each Vial contain Cefepime injection 1gm.
50	168	2709	Cetrorelix Injection: Each vial to contain Cetrorelix 0.25mg.
51	168	2710	Dapagliflozin+ Sitagliptin+ Metformin tab/cap:Each Tab/Cap to contain Dapagliflozin 10mg+ Sitagliptin 100mg+ Metformin 1000mg
52	168	2711	Cefditoren Pivoxil suspension:Each 5 ml of reconstituted suspension contains: Cefditoren Pivoxil equivalent to Cefditoren 100 mg, 30ml bottle
53	168	2712	Gliclazide+Metformin Tab/cap: Each uncoated bi-layered scored tablet contains gliclazide I.P. (as extended release).... 60 mg and metformin hydrochloride I.P. (as extended release).... 1000 mg
54	168	2713	Cefditoren Pivoxil Dispersible Tablet: Each uncoated Dispersible Tablet contains : Cefditoren Pivoxil equivalent to Cefditoren 50 mg
55	168	2714	Thyroxine tab/cap:Each Tab/cap to contain Thyroxine 62.5 mcg
56	168	2715	Thyroxine tab/cap: Each Tab/cap to contain Thyroxine 88 mcg
57	168	2721	Follitropin Alfa 450 IU (r-hFSH) + Lutropin Alfa 225 IU (r-FSH) Pre-filled Pen Packing : Vial/Amp/PFS
58	168	2722	Isavuconazole tab/cap: Each Tab/Cap to contain Isavuconazole 100mg
59	168	2723	Isavuconazole injection:Each vial to contain Isavuconazole 200mg
60	168	2724	Linezolid Solution for Injection(2mg/ml): Each 100ml contains Linezolid 0.2gm, Dextrose Anhydrous IP 5gm
61	168	2728	Minocycline Injection:Each Vial/Amp to contain Minocycline 100mg
62	168	2729	Oseltamivir Tab/Cap: Each Tab/Cap to contain Oseltamivir





ए. ए. सी. ई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			75mg
63	168	2732	Propylthiouracil Cap/Tab:Each Tab/Cap to contain Propylthiouracil 50mg
64	168	2734	Repaglinide Tab/Cap:Each Tab/Cap to contain Repaglinide 1mg
65	168	2735	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 3mg
66	168	2736	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 7mg
67	168	2737	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 14mg
68	168	2741	Sofosbuvir +Velpatasvir Cap/Tab: Each Tab/Cap to contain Sofosbuvir 400mg+ Velpatasvir 100mg
69	168	2742	Somatogron 24 mg/1.2 ml (solution for sub-cutaneous injection in pre-filled pen)
70	168	2743	Somatogron 60 mg/1.2 ml (solution for sub-cutaneous injection in pre-filled pen)
71	168	1284b	Lignocaine Jelly- Each Tube to contain: Lignocaine2%,30gmTube
72	168	132a	Danazol Tab/Cap- Each Tab/Cap to contain: Danazol 100mg.
73	168	185a	Pyrazinamide Tab/Cap- Each Tab/Cap to contain: Pyrazinamide 500mg.
74	168	185b	Pyrazinamide Tab/Cap- Each Tab/Cap to contain: Pyrazinamide 750mg.
75	168	186b	Isoniazide Tab/Cap - Each Tab/Cap to contain: Isoniazide 300mg.
76	168	400a	Propofol Inj- Each Vial to contain: Propofol 1%,10ml Vial
77	168	576a	Gliclazide MR Tab/Cap- Each MR Tab/Cap to contain: Gliclazide 30mg.
78	168	576b	Gliclazide MR Tab/Cap- Each Modified Release Tab/Cap to contain: Gliclazide 60mg.
79	168	603b	Intravenous Lipid Soln 20%- Each 100ml to contain: Fat Emulsion Containing Fractionated Soyabean Oil 20gm, Fractionated Egg Phospholipids 1.2gm, Glycerol 2.2gm.,250ml

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	MICRON PHARMACEUTICALS	134	Prednisolone Tab/Cap-Each Tab/Cap to contain Prednisolone 5 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.34/1 Tab	Paise Thirty Four Only	L-1
168	Wings Biotech LLP	134	Prednisolone Tab/Cap-Each Tab/Cap to contain Prednisolone 5 mg	1 Tab/Cap	Same as in Item	15 Tab	0.35/1 Tab	Paise Thirty Five Only	L-2
168	Primus Pharmaceuticals	134	Prednisolone Tab/Cap-Each Tab/Cap to contain Prednisolone 5 mg.	1 Tab/Cap	P.SOLONE - 5	10 Tab	0.45/1 Tab	Paise Forty Five Only	L-3
168	Pulse Pharmaceuticals Pvt Ltd	137	Acarbose Tab/Cap-Each Tab/Cap to contain: Acarbose 50 mg	1 Tab/Cap	Glystal 50	10 Tab	2.05/1 Tab	Rupees Two Paise Five Only	L-1
168	Primus Pharmaceuticals	137	Acarbose Tab/Cap-Each Tab/Cap to contain: Acarbose 50 mg	1 Tab/Cap	P-CARB 50	10 Tab	2.60/1 Tab	Rupees Two Paise Sixty Only	L-2
168	Bal Pharma Ltd	137	Acarbose Tab/Cap-Each Tab/Cap to contain: Acarbose 50 mg	1 Tab/Cap	RECARB 50	10 Tab	2.61/1 Tab	Rupees Two Paise Sixty One Only	L-3
168	Hindustan Laboratories Limited	172	Erythromycin Oral Susp-Each 5ml to contain: Erythromycin 125mg, 30ml Bottle	1ml	HITHROCIN	30ml Bottle	0.65/1ml	Paise Sixty Five Only	L-1
168	Hindustan Laboratories Limited	202	Diethyl Carbamazine Syp-Each 5ml to contain: Diethyl Carbamazine Citrate 120mg., 100ml Bottle	1ml	HIZYME	100ml Bottle	0.45/1ml	Paise Forty Five Only	L-1
168	ALPA LABORATORIES LTD	251	Lignocaine Inj-Each vial to contain: Lignocaine Hcl 2%w/v., 30ml Vial	1 Vial	Same as in Item	30ml Vial	12.90/1 Vial	Rupees Twelve Paise Ninety Only	L-1
168	Aculife Healthcare Pvt. Ltd.	251	Lignocaine Inj-Each vial to contain: Lignocaine Hcl 2% w/v.,30ml Vial	1 Vial	Lignonext 2%	30ml Vial	24.00/1 Vial	Rupees Twenty Four Only	L-2
168	Aculife Healthcare Pvt. Ltd.	277	Sterile Water for Inj-Each Amp to contain: Sterile Water for Injection,5ml Amp	1 Amp	Same as in Item	5ml Amp	2.30/1 Amp	Rupees Two Paise Thirty Only	L-1

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Tablets (India) Limited	426	Neostigmine Inj- Each ml to contain: Neostigmine 0.5mg,1ml Amp	1 Amp	Tilstigmin	1ml Ampoule	2.96/1 Amp	Rupees Two Paise Ninety Six Only	L-1
168	Primus Pharmaceuticals	426	Neostigmine Inj-Each ml to contain: Neostigmine 0.5mg, 1ml Amp	1 Amp	NEOPRIME 0.5mg/ml	1ml Ampoule	3.20/1 Amp	Rupees Three Paise Twenty Only	L-2
168	Naprod Life Sciences Pvt. Ltd.	447	Rocuronium Inj-Each ml to contain: Rocuronium 10mg, 5ml Vial/Amp	1 Vial/Amp	Aesroc	1 Vial	149/1 Vial	Rupees One Hundred Forty Nine Only	L-1
168	Wings Biotech LLP	479	Prednisolone Tab/Cap- Each Tab/Cap to contain: Prednisolone 10 mg	1 Tab/Cap	Same as in Item	10 Tab	0.66/1 Tab	Paise Sixty Six Only	L-1
168	MICRON PHARMACEUTICALS	479	Prednisolone Tab/Cap-Each Tab/Cap to contain: Prednisolone 10 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.69/1 Tab	Paise Sixty Nine Only	L-2
168	Primus Pharmaceuticals	479	Prednisolone Tab/Cap-Each Tab/Cap to contain: Prednisolone 10 mg.	1 Tab/Cap	P.SOLONE-10	10 Tab	0.88/1 Tab	Paise Eighty Eight Only	L-3
168	ALPA LABORATORIES LTD	1164	Hydrocortisone Sod. Succinate Inj-Each vial to contain: Hydrocortisone Sod. Succinatee qv. to Hydrocortisone 100 mg	1 Vial	Same as in Item	1 Vial	11.85/1 Vial	Rupees Eleven Paise Eighty Five Only	L-1
168	Biocon Biologics Limited	1173	Human Insulin Biphasic Mixed (30% + 70%)Each vial to contain: Human Insulin Biphasic 30% Soluble + 70% NPH 40 units / ml.,10ml Vial	1 Vial	INSUGEN 30/70 (BIPHASIC)	10ml Vial	83.00/1 Vial	Rupees Eighty Three Only	L-1
168	Aculife Healthcare Pvt. Ltd.	1318	Glycine Soln-Each Bottle/Bag to contain: Glycine 1.5% (1.5 gm /Glycine 1.5% (1.5 gm / 100 ml),3Ltr Bottle/Bag	1 Bottle/Bag	Same as in Item	3000ml Bottle/Bag	240/1 Bottle	Rupees Two Hundred Forty Only	L-1

क.स.बी.नि.
ESIC

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Tablets (India) Limited	1322	Amino Acid (For IV Infusion)- Each ml to contain: L-Arginine Hcl 8.0 mg. L-Histidine Hcl. 4.0mg. L-Isoleucine 5.5mg. L-Lysine Hcl. 22.3mg. L-Methionine 7.1mg. L-Threonine 5.4mg. L-Phenylalanine 8.7mg. L- Leucine 12.3 mg. L-Valine 6.1 mg. Glycine 10.0mg. L-Tryptophan 1.8mg.Sorbitol 50.0 mg.,200ml Glass Bottle	1ml	Astymim-3	200ml Bottle	0.63/1ml	Paise Sixty Three Only	L-1
168	T. Walker's Pharmaceuticals Pvt Ltd	1326	Sodium Bi-carbonate Injection IP 10.0ml Ampoule Sodium Bi-carbonate IP (75mg/ml) Water For Injection IP (q.s. to 1.0ml)	1 Amp	Same as in Item	10ml Ampoule	7.80/1 Amp	Rupees Seven Paise Eighty Only	L-1
168	Aculife Healthcare Pvt. Ltd.	1389	Mannitol + Glycerin Infusion- Each Bottle to contain: Mannitol I.P. 10%, Glycerin I.P. 10%,100ml Bottle	1ml	Reotol G	100ml Bottle	1.00/1ml	Rupee One Only	L-1
168	Macleods Pharmaceuticals Limited	1484	Imipenem + Cilastatin Inj-Each vial to contain: Imipenem 500mg, Cilastatin 500mg	1 Vial	ZILAMAC 500	1 Vial	159.90/1 Vial	Rupees One Hundred Fifty Nine Paise Ninety Only	L-1
168	Primus Pharmaceuticals	1484	Imipenem + Cilastatin Inj-Each vial to contain: Imipenem 500mg, Cilastatin 500mg	1 Vial	MINEM - 1 GM	1 Vial	161.00/1 Vial	Rupees One Hundred Sixty One Only	L-2
168	MAAN PHARMACEUTICALS LTD.	1484	Imipenem + Cilastatin Inj-Each vial to contain: Imipenem 500mg, Cilastatin 500mg	1 Vial	Same as in Item	1 Vial	207.00/1 Vial	Rupees Two Hundred Seven Only	L-3
168	Biodeal Pharmaceuticals Ltd.	1550	Linezolid Tab/Cap-Each Tab/Cap to contain: Linezolid 600mg	1 Tab/Cap	Same as in Item	10 Tab	4.29/1 Tab	Rupees Four Paise Twenty Nine Only	L-1
168	Primus Pharmaceuticals	1550	Linezolid Tab/Cap-Each Tab/Cap to contain: Linezolid 600mg	1 Tab/Cap	OXAMUS-600	10 Tab	5.20/1 Tab	Rupees Five Paise Twenty Only	L-2

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	UNICURE INDIA LTD	1550	Linezolid Tab/Cap-Each Tab/Cap to contain: Linezolid 600mg	1 Tab/Cap	Same as in Item	10 Tab	5.34/1 Tab	Rupees Five Paise Thirty Four Only	L-3
168	Glenmark Pharmaceuticals Limited	1559	Linezolid Inj-Each Vial/bag to contain: Linezolid 600mg	1 Vial/Bag	LIZOLID I.V.	300ml Single Dose Container	56.00/1 Vial	Rupees Fifty Six Only	L-1
168	FRESENTIUS KABI INDIA PRIVATE LIMITED	1559	Linezolid Inj-Each Vial/Bag to contain: Linezolid 600mg	1 Vial/Bag	Kabizolid 300ml Freeflex Bag	300ml Bag	115.00/1 Vial	Rupees One Hundred Fifteen Only	L-2
168	Morepen Laboratories Limited	1591	Saxagliptin Tab/Cap - Each Tab/Cap to contain: Saxagliptin 2.5mg	1 Tab/Cap	Saxaquest 2.5	10 Tab	3.47/1 Tab	Rupees Three Paise Forty Seven Only	L-1
168	MICRON PHARMACEUTICALS	1700	Ivermectin Tab/Cap- Each Tab/Cap to contain: Ivermectin 6mg	1 Tab/Cap	Same as in Item	10 Tab	0.59/1 Tab	Paise Fifty Nine Only	L-1
168	MASCOT HEALTH SERIES PVT LTD	1765	Voglibose Tab/Cap - Each Tab/Cap to contain: Voglibose 0.2 mg	1 Tab/Cap	VOGLIB-0.2	10 Tab	0.39/1 Tab	Paise Thirty Nine Only	L-1
168	Morepen Laboratories Limited	1765	Voglibose Tab/Cap - Each Tab/Cap to contain: Voglibose 0.2 mg	1 Tab/Cap	VOGLIMORE-2	10 Tab	0.40/1 Tab	Paise Forty Only	L-2
168	Windlas Biotech Limited	1765	Voglibose Tab/Cap - Each Tab/Cap to contain: Voglibose 0.2 mg	1 Tab/Cap	WINBOSE 0.2	10 Tab	0.40/1 Tab	Paise Forty Only	L-2
168	MANKIND PHARMA LIMITED	1765	Voglibose Tab/Cap - Each Tab/Cap to contain: Voglibose 0.2 mg	1 Tab/Cap	Same as in Item	15 Tab	0.41/1 Tab	Paise Forty One Only	L-3
168	Primus Pharmaceuticals	1771	Clindamycin Tab/Cap- Each Tab/Cap to contain: Clindamycin 300mg	1 Tab/Cap	ACNIS-300	10 Cap	3.85/1 Cap	Rupees Three Paise Eighty Five Only	L-1
168	MICRON PHARMACEUTICALS	1771	Clindamycin Tab/Cap- Each Tab/Cap to contain: Clindamycin 300mg	1 Tab/Cap	Same as in Item	10 Cap	3.96/1 Cap	Rupees Three Paise Ninety Six Only	L-2
168	Macleods Pharmaceuticals Limited	1771	Clindamycin Tab/Cap- Each Tab/Cap to contain: Clindamycin 300mg	1 Tab/Cap	CLINDASURE 300	10 Cap	4.49/1 Cap	Rupees Four Paise Forty Nine Only	L-3

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Primus Pharmaceuticals	1772	Clindamycin Inj-Each Vial to contain: Clindamycin 600 mg ,4ml Amp	1 Amp	ACNIS-600 INJECTION	4 ml Ampoule	59.00/1 Amp	Rupees Fifty Nine Only	L-1
168	Reliance Life Sciences Pvt. Ltd.	1779	Interferon Beta 1-A Inj- Each PFS/PFP to contain: Interferon beta 1-a 30 mcg (6 million IU).	1PFS/PFP	Relibeta	1PFS	4900/1 PFS	Rupees Four Thousand Nine Hundred Only	L-1
168	Glenmark Pharmaceuticals Limited	1838	Garenoxacin Tab/Cap-Each film coated Tab/Cap to contains: Garenoxacin Mesylate equivalent to Garenoxacin 200mg, Excipients-q.s.	1 Tab/Cap	ZINOX	10 Tab	48.95/1 Tab	Rupees Forty Eight Paise Ninety Five Only	L-1
168	Morepen Laboratories Limited	1894	Saxagliptin & Metformin(ER) Tab/Cap- Each film coated Tab/Cap to contain: Saxagliptin 5 mg + Metformin Hcl 500mg (ER)	1 Tab/Cap	Saxaquest M 5/500	10 Tab	7.12/1 Tab	Rupees Seven Paise Twelve Only	L-1
168	Morepen Laboratories Limited	1896	Linagliptin Tab/Cap- Each film coated Tab/Cap to contain: Linagliptin 5mg	1 Tab/Cap	Linaworth-5	10 Tab	0.66/1 Tab	Paise Sixty Six Only	L-1
168	Signature Phytochemical Industries	1896	Linagliptin Tab/Cap-Each film coated Tab/Cap to contain: Linagliptin 5mg	1 Tab/Cap	LINAGENTA	10 Tab	1.16/1 Tab	Rupee One Paise Sixteen Only	L-2
168	Cipla Ltd.	1896	Linagliptin Tab/Cap- Each film coated Tab/Cap to contain: Linagliptin 5mg	1 Tab/Cap	Linacip	15 Tab	1.19/1 Tab	Rupee One Paise Nineteen Only	L-3
168	Tablets (India) Limited	1902	Cefixime And Pre & Probiotic Tab/Cap- Each Tab/cap. to contain: Cefixime IP as Trihydrate equivalent to Anhydrous Cefixime 200 mg and Each Inner cap to contain: Sterptococcus Faecalis T-110 JPC 60million Clostridium Butyricum TO-A 4 million Bacillus MesentericusTO-AJPC 2 million Lactic Acid Bacillus 100million	1 Tab/Cap	Syncefix	10 Cap	14.31/1 Cap	Rupees Fourteen Paise Thirty One Only	L-1
168	Biodeal Pharmaceuticals Ltd.	2034	Teneligiptin 20mg Tab/Cap-Each Tab/Cap to contain: Teneligiptin 20mg	1 Tab/Cap	Same as in Item	10 Tab	0.49/1 Tab	Paise Forty Nine Only	L-1

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Morepen Laboratories Limited	2034	Teneligiptin 20mg Tab/Cap- Each Tab/Cap to contain: Teneligiptin 20mg	1 Tab/Cap	Teneright-20	10 Tab	0.60/1 Tab	Paise Sixty Only	L-2
168	Bal Pharma Ltd	2034	Teneligiptin 20mg Tab/Cap- Each Tab/Cap to contain: Teneligiptin 20mg	1 Tab/Cap	DIATEN 20	10 Tab	0.69/1 Tab	Paise Sixty Nine Only	L-3
168	UNICURE INDIA LTD	2236	Metformin ER Tab/Cap-Each uncoated Extended Release Tab/Cap contains: Metformin 1000 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.76/1 Tab	Paise Seventy Six Only	L-1
168	Wings Biotech LLP	2236	Metformin ER Tab/Cap-Each uncoated Extended Release Tab/Cap contains: Metformin 1000 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.78/1 Tab	Paise Seventy Eight Only	L-2
168	Hindustan Laboratories Limited	2236	Metformin ER Tab/Cap-Each uncoated Extended Release Tab/Cap contains: Metformin 1000 mg.	1 Tab/Cap	HITRALIN 1000	10 Tab	0.79/1 Tab	Paise Seventy Nine Only	L-3
168	Morepen Laboratories Limited	2236	Metformin ER Tab/Cap-Each uncoated Extended Release Tab/Cap contains: Metformin 1000 mg.	1 Tab/Cap	Myformin PR 1GM	10 Tab	0.79/1 Tab	Paise Seventy Nine Only	L-3
168	RIVPRA FORMULATION PVT. LTD,	2241	Valacydovir Tab/Cap-Each Film Coated Tab/Cap Contains: Valacydovir Hydrochloride USP Equivalent to Valacydovir 500mg	1 Tab/Cap	VALCIMEN-500	3 Tab	18.00/1 Tab	Rupees Eighteen Only	L-1
168	Zydus Healthcare Limited	2347	Heparin Oint/Cream-Each gm to contain: Heparin Sodium 50 IU, Benzyl Nicotinate 2mg,20gm Tube	1gm	THROMBOPHOB	20 gm	5.75/1gm	Rupees Five Paise Seventy Five Only	L-1
168	Aculife Healthcare Pvt. Ltd.	2356	Ofloxacin, Sodium Chloride Soln- Each 100ml to contain: Ofloxacin IP 200mg, Sodium Chloride 900mg, 100ml Bottle	1ml	Sinoflox	100ml Bottle	0.18/1ml	Paise Eighteen Only	L-1
168	Aculife Healthcare Pvt. Ltd.	2363	Normal Saline- Each Bottle/Bag to contain: Normal Saline 0.9%, 3 Litre Bottle/Bag	Bottle/Bag	Same as in Item	3000ml Bottle/Bag	*200/1 Bottle	Rupees Two Hundred Only	L-1

[*Unit cost is too small for calculation purpose. Therefore, in this case 1-Bottle of 3 Litre is taken as unit]

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Primus Pharmaceuticals	2377	Atropine Inj-Each ml to contain: Atropine 0.6 mg,1ml Vial/Amp	1 Vial/Amp	ATROCAM INJECTION	1ml Ampoule	3.75/1 Amp	Rupees Three Paise Seventy Five Only	L-1
168	ALPA LABORATORIES LTD	2377	Atropine Inj-Each ml to contain: Atropine 0.6mg,1mlVial/Amp	1 Vial/Amp	Same as in Item	1ml Ampoule	4.34/1 Amp	Rupees Four Paise Thirty Four Only	L-2
168	Dr. Reddy's Laboratories Limited	2381	Darbepoetin Inj- Each PFS to contain: Darbepoetin Alfa 60mcg	1 PFS	Cresp 60	1 PFS	989/1 PFS	Rupees Nine Hundred Eighty Nine Only	L-1
168	Glenmark Pharmaceuticals Limited	2384	Remogliflozin Tab/Cap-Each Film Coated Tab/Cap to contain: Remogliflozin Etabonate 100mg, Excipients-q.s.	1 Tab/Cap	Remo 100 mg	15 Tab	10.64/1 Tab	Rupees Ten Paise Sixty Four Only	L-1
168	HAB Pharmaceuticals & Research Ltd	2385	Mefipristone + Misoprostol- Each Kit to contain: Mefipristone 200mg (01 Tab/Cap), Misoprostol 200 mcg (04 Tab/Cap)	1 Kit	MICOPHY M-KIT	1 Kit	66.00/1 Kit	Rupees Sixty Six Only	L-1
168	UNICURE INDIA LTD	2396	Dinoprostone Gel-Each Tube to contain: Dinoprostone 0.5mg, 3gm Tube	1gm	Same as in Item	3gm	68.99/1gm	Rupees Sixty Eight Paise Ninety Nine Only	L-1
168	Tablets (India) Limited	2461	Cefpodoxime+Prebiotic Tab/Cap-Each Tab/ Hard Cellulose Cap contains:Cefpodoxime Proxetil IP equivalent to Cefpodoxime 200mg Each inner Tab/ Hard cellulose Cap contains:Streptococcus faecalis T-110 JPC 60 Million, Clostridium butyricum TO-A 4 Million, Bacillus mesentericus TO-A JPC 2 Million, Lactic acid bacillus 100 Million (Lactobacillus sporogenes)	1 Tab/Cap	Synpod	10 Cap	27.93/1 Cap	Rupees Twenty Seven Paise Ninety Three Only	L-1
168	Cipla Ltd.	2464	Artemether 80mg+Lumefantrine 480mg Inj/ Dispersible Tab/Cap-80mg+Lumefantrine 480mg	1 Tab/Cap	LUMET 80	6 Tab	6.55/1 Tab	Rupees Six Paise Fifty Five Only	L-1
168	Aculife Healthcare Pvt. Ltd.	2465	Normal Saline/ Sodium Chloride Soln- Each Bottle to contain: Normal Saline/ Sodium Chloride 0.45% IV,500ml Bottle	1ml	Same as in Item	500ml Bottle	0.06/1ml	Paise Six Only	L-1

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Aculife Healthcare Pvt. Ltd.	2466	Normal Saline/ Sodium Chloride Soln- Each Bottle to contain: Normal Saline/ Sodium Chloride 0.9%, 100ml Bottle	1ml	Same as in Item	100ml Bottle	0.16/1ml	Paise Sixteen Only	L-1
168	Biocon Biologics Limited	2468	Insulin Human Regular/ Soluble/ Actrapid- Each Vial/Amp to contain: Insulin Human Regular/Soluble/Actrapid 40IU/ML, 10ml Vial/Amp	1 Vial/Amp	INSUGEN-R(REGULAR) 40IU/mL	10ml Vial	83/1 Vial	Rupees Eighty Three Only	L-1
168	Indoco Remedies Ltd.	2700	Alogliptin Tab/Cap: Each tab/cap to contain Alogliptin 25mg	1 Tab/Cap	ALOJA 25	10 Tab	11.74/1 Tab	Rupees Eleven Paise Seventy Four Only	L-1
168	Indoco Remedies Ltd.	2701	Alogliptin + Metformin Tab/Cap: Each Tab/Cap to contain Alogliptin 12.5mg + Metformin 500mg Tab/Cap	1 Tab/Cap	ALOJA-M	10 Tab	7.56/1 Tab	Rupees Seven Paise Fifty Six Only	L-1
168	Zuventus Healthcare Limited	2702	Amoxycillin+ Clavulanic Acid Drop: Each ml to contain Amoxycillin 80 mg, Clavulanic Acid 11.4 mg, Pack of 10 to 15 ml	1ml	AUGPEN DROPS	10ml Bottle	5.00/1ml	Rupees Five Only	L-1
168	Aculife Healthcare Pvt. Ltd.	2704	Balanced Salt Solution- 500ml.	1ml	Plasma SOL	500ml Bottle	0.25/1ml	Paise Twenty Five Only	L-1
168	Macleods Pharmaceuticals Limited	2706	Cefepime injection: Each Vial contain Cefepime injection 1gm.	1 Vial	KEFPIME 1g	1 Vial	56.90/1 Vial	Rupees Fifty Six Paise Ninety Only	L-1
168	Primus Pharmaceuticals	2706	Cefepime injection: Each Vial contain Cefepime injection 1gm.	1 Vial	VAMPIME INJECTION	1 vial	77.00	Rupees Seventy Seven Only	L-2
168	Theon Pharmaceuticals Limited	2706	Cefepime injection: Each Vial contain Cefepime injection 1gm.	1 Vial	Same as in Item	1 Vial	91.91/1 Vial	Rupees Ninety One Paise Ninety One Only	L-3

ESIC

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	BDR Pharmaceuticals International Private Limited	2709	Cetorelix Injection: Each vial to contain Cetorelix 0.25mg.	1 Vial	BDTROLIX	1 Vial	129.78/1 Vial	Rupees One Hundred Twenty Nine Paise Seventy Eight Only	L-1
168	Bharat Serums and Vaccines Limited	2709	Cetorelix Injection: Each vial to contain Cetorelix 0.25mg.	1 Vial	ASPORELIX 0.25	Vial	410.00/1 Vial	Rupees Four Hundred Ten Only	L-2
168	MASCOT HEALTH SERIES PVT LTD	2710	Dapagliflozin+ Sitagliptin+ Metformin tab/cap: Each Tab/Cap to contain Dapagliflozin 10mg+ Sitagliptin 100mg+ Metformin 1000mg	1 Tab/Cap	SITAROZ M GOLD	10 Tab	2.68/1 Tab	Rupees Two Paise Sixty Eight Only	L-1
168	Theon Pharmaceuticals Limited	2710	Dapagliflozin+ Sitagliptin+ Metformin tab/cap: Each Tab/Cap to contain Dapagliflozin 10mg+ Sitagliptin 100mg+ Metformin 1000mg	1 Tab/Cap	Same as in Item	10 Tab	4.95/1 Tab	Rupees Four Paise Ninety Five Only	L-2
168	Windlas Biotech Limited	2710	Dapagliflozin+ Sitagliptin+ Metformin Tab/Cap: Each Tab/Cap to contain Dapagliflozin 10mg+ Sitagliptin 100mg+ Metformin 1000mg	1 Tab/Cap	DAPAGLIPT SM 10/1000	10 Tab	6.90/1 Tab	Rupees Six Paise Ninety Only	L-3
168	Zuventus Healthcare Limited	2711	Cefditoren Pivoxil Suspension: Each 5 ml of reconstituted suspension contains: Cefditoren Pivoxil equivalent to Cefditoren 100 mg, 30ml bottle	1ml	ZOSTUM-O 100	30ml Bottle	4.74/1ml	Rupees Four Paise Seventy Four Only	L-1
168	Dr. Reddy's Laboratories Limited	2712	Gliclazide+Metformin Tab/Cap: Each uncoated bi-layered scored tablet contains gliclazide I.P. (as extended release)60mg and metformin hydrochloride I.P. (as extended release) 1000mg	1 Tab/Cap	Reclimet-XR Forte	15 Tab	3.50/1 Tab	Rupees Three Paise Fifty Only	L-1

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Servier India Private Limited	2712	Gliclazide+Metformin Tab/Cap: Each uncoated bi-layered scored tablet contains gliclazide I.P. (As extended release) 60mg and metformin hydrochloride I.P. (as extended release) 1000mg	1 Tab/Cap	DIAMICRON XR MEX 60/1000	10 Tab	18.02/1 Tab	Rupees Eighteen Paise Two Only	L-2
168	Zuventus Healthcare Limited	2713	Cefditoren Pivoxil Dispersible Tablet: Each uncoated Dispersible Tablet contains: Cefditoren Pivoxil equivalent to Cefditoren 50mg	1 Tab	ZOSTUM-O 50 DT	10 Tab	13.50/1 Tab	Rupees Thirteen Paise Fifty Only	L-1
168	Biodeal Pharmaceuticals Ltd.	2714	Thyroxine Tab/Cap: Each Tab/cap to contain Thyroxine 62.5 mcg	1 Tab/Cap	Same as in Item	100 Tab	0.19/1 Tab	Paise Nineteen Only	L-1
168	Biodeal Pharmaceuticals Ltd.	2715	Thyroxine Tab/Cap: Each Tab/cap to contain Thyroxine 88 mcg	1 Tab/Cap	Same as in Item	100 Tab	0.21/1 Tab	Paise Twenty One Only	L-1
168	Macleods Pharmaceuticals Limited	2715	Thyroxine Tab/Cap: Each Tab/cap to contain Thyroxine 88 mcg	1 Tab/Cap	THYROX 88	120 Tab	0.64/1 Tab	Paise Sixty Four Only	L-2
168	Merck Specialities Private Limited	2721	Follitropin Alfa 450 IU (r-hFSH) + Lutropin Alfa 225 IU (r-FSH) Pre-filled Pen, Packing: Vial/Amp/PFS	1 Vial/Amp/PFS	Pergoveris 450 IU (Mfd. by- Merck Serono S.p.A Italy)	1 Multidose PFS	11100/1 PFS	Rupees Eleven Thousand One Hundred Only	L-1
168	BDR Pharmaceuticals International Private Limited	2722	Isavuconazole Tab/Cap: Each Tab/Cap to contain Isavuconazole 100mg	1 Tab/Cap	ZISAVEL-100	7 Cap	396/1 Cap	Rupees Three Hundred Ninety Six Only	L-1
168	BDR Pharmaceuticals International Private Limited	2723	Isavuconazole injection: Each vial to contain Isavuconazole 200mg	1 Vial/Amp	ZISAVEL-200	1 Vial	1560.60/1 Vial	Rupees One Thousand Five Hundred Sixty Paise Sixty Only	L-1

ESIC

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	FRESENIUS KABI INDIA PRIVATE LIMITED	2724	Linezolid Solution for Injection(2mg/ml): Each 100ml contains Linezolid 0.2gm, Dextrose Anhydrous IP 5gm	1ml	Kabizolid 100ml Freeflex Bag	100ml ml Bag	1.10/1ml	Rupee One Paise Ten Only	L-1
168	BDR Pharmaceuticals International Private Limited	2728	Minocycline Injection: Each Vial/Amp to contain Minocycline 100mg	1 Vial/Amp	BD-MINO 100	Vial	165/1 Vial	Rupees One Hundred Sixty Five Only	L-1
168	MICRON PHARMACEUTICALS	2729	Oseltamivir Tab/Cap: Each Tab/Cap to contain Oseltamivir 75mg	1 Tab/Cap	Same as in Item	10 Cap	9.90/1 Cap	Rupees Nine Paise Ninety Only	L-1
168	Macleods Pharmaceuticals Limited	2729	Oseltamivir Tab/Cap: Each Tab/Cap to contain Oseltamivir 75mg	1 Tab/Cap	FLUVIA	10 Cap	26.70/1 Cap	Rupees Twenty Six Paise Seventy Only	L-2
168	Overseas Health Care Private Limited	2729	Oseltamivir Tab/Cap: Each Tab/Cap to contain Oseltamivir 75mg	1 Tab/Cap	FLUCOVER	10 Cap	29.99/1 Cap	Rupees Twenty Nine Paise Ninety Nine Only	L-3
168	Macleods Pharmaceuticals Limited	2732	Propylthiouracil Cap/Tab: Each Tab/Cap to contain Propylthiouracil 50mg	1 Tab/Cap	PTU	100 Tab	4.90/1 Tab	Rupees Four Paise Ninety Only	L-1
168	MESMER PHARMACEUTICALS	2734	Repaglinide Tab/Cap: Each Tab/Cap to contain Repaglinide 1mg	1 Tab/Cap	LUNCH ON-1	10 Tab	0.59/1 Tab	Paise Fifty Nine Only	L-1
168	Torrent Pharmaceuticals Ltd.	2734	Repaglinide Tab/Cap: Each Tab/Cap to contain Repaglinide 1mg	1 Tab/Cap	EUREPA-1	15 Tab	2.99/1 Tab	Rupees Two Paise Ninety Nine Only	L-2
168	Novo Nordisk India Private limited	2735	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 3mg	1 Tab/Cap	Rybelsus 3mg (Mfd. Novo Nordisk A/S, Denmark)	10 Tab	218.73/1 Tab	Rupees Two Hundred Eighteen Paise Seventy Three Only	L-1
168	Novo Nordisk India Private limited	2736	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 7mg	1 Tab/Cap	Rybelsus 7mg (Mfd. Novo Nordisk A/S, Denmark)	10 Tab	242.88/1 Tab	Rupees Two Hundred Forty Two Paise Eighty Eight Only	L-1

ESIC

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Novo Nordisk India Private limited	2737	Semaglutide Tab/Cap: Each Tab/Cap to contain Semaglutide 14mg	1 Tab/Cap	Rybelsus 14mg (Mfd. Novo Nordisk A/S, Denmark)	10 Tab	267.03/1 Tab	Rupees Two Hundred Sixty Seven Paise Three Only	L-1
168	Zydus Lifesciences Limited	2741	Sofosbuvir +Velpatasvir Cap/Tab: Each Tab/Cap to contain Sofosbuvir 400mg+ Velpatasvir 100mg	1 Tab/Cap	SoviHep V	28 Tab	105.00/1 Tab	Rupees One Hundred Five Only	L-1
168	Pfizer Products India Private Limited	2742	Somatrogon 24 mg/1.2 ml (solution for sub-cutaneous injection in pre-filled pen)	1 Injection/ Pre filled Pen	GENRYZON 24mg (Mfd. by Pfizer Manufacturing, Belgium NV)	1 Multidose Prefilled Pen	9360/1 PFP	Rupees Nine Thousand Three Hundred Sixty Only	L-1
168	Pfizer Products India Private Limited	2743	Somatrogon 60 mg/1.2 ml (solution for sub-cutaneous injection in pre-filled pen)	1 Injection/ Pre filled Pen	GENRYZON 60mg (Mfd. by Pfizer Manufacturing, Belgium NV)	1 Multidose Prefilled Pen	23400/1 PFP	Rupees Twenty Three Thousand Four Hundred Only	L-1
168	ALPA LABORATORIES LTD	1284b	Lignocaine Jelly-Each Tube to contain: Lignocaine2%,30gmTube	1gm	Same as in Item	30gm Tube	0.43/1gm	Paise Forty Three Only	L-1
168	MICRON PHARMACEUTICALS	132a	Danazol Tab/Cap-Each Tab/Cap to contain: Danazol 100mg.	1 Tab/Cap	Same as in Item	10 Cap	5.40/1 Cap	Rupees Five Paise Forty Only	L-1
168	MICRON PHARMACEUTICALS	185a	Pyrazinamide Tab/Cap-Each Tab/Cap to contain: Pyrazinamide 500mg.	1 Tab/Cap	Same as in Item	10 Tab	1.44/1 Tab	Rupee One Paise Forty Four Only	L-1
168	MICRON PHARMACEUTICALS	185b	Pyrazinamide Tab/Cap-Each Tab/Cap to contain: Pyrazinamide 750mg.	1 Tab/Cap	Same as in Item	10 Tab	1.98/1 Tab	Rupee One Paise Ninety Eight Only	L-1
168	Macleods Pharmaceuticals Limited	185b	Pyrazinamide Tab/Cap-Each Tab/Cap to contain: Pyrazinamide 750mg.	1 Tab/Cap	MACROZIDE 750	10 Tab	5.77/1 Tab	Rupees Five Paise Seventy Seven Only	L-2
168	MICRON PHARMACEUTICALS	186b	Isoniazide Tab/Cap-Each Tab/Cap to contain: Isoniazide 300mg.	1 Tab/Cap	Same as in Item	10 Tab	0.81/1 Tab	Paise Eighty One Only	L-1

DG-ESIC Central Rate Contract No.168 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
168	Naprod Life Sciences Pvt. Ltd.	400a	Propofol Inj-Each Vial to contain: Propofol 1%,10ml Vial	1 Vial	Dipventin	1 Vial	29.00/1 Vial	Rupees Twenty Nine Only	L-1
168	Aculife Healthcare Pvt. Ltd.	400a	Propofol Inj- Each Vial to contain: Propofol 1%,10ml Vial	1 Vial	Quifol 1%	10ml Vial	52.00/1 Vial	Rupees Fifty Two Only	L-2
168	Bal Pharma Ltd	576a	Gliclazide MR Tab/Cap-Each MR Tab/Cap to contain: Gliclazide 30mg.	1 Tab/Cap	DIABEND MR 30	10 Tab	0.81/1 Tab	Paise Eighty One Only	L-1
168	MICRO LABS LTD	576a	Gliclazide MR Tab/Cap-Each MR Tab/Cap to contain: Gliclazide 30mg.	1 Tab/Cap	DIANORM OD 30	10 Tab	0.89/1 Tab	Paise Eighty Nine Only	L-2
168	Dr. Reddy's Laboratories Limited	576a	Gliclazide MR Tab/Cap-Each MR Tab/Cap to contain: Gliclazide 30mg	1 Tab/Cap	Reclide MR 30	15 Tab	0.92/1 Tab	Paise Ninety Two Only	L-3
168	Hindustan Laboratories Limited	576b	Gliclazide MR Tab/Cap-Each Modified Release Tab/Cap to contain: Gliclazide 60mg.	1 Tab/Cap	HIZID MR	10 Tab	1.15/1 Tab	Rupee One Paise Fifteen Only	L-1
168	Bal Pharma Ltd	576b	Gliclazide MR Tab/Cap-Each Modified Release Tab/Cap to contain: Gliclazide 60mg.	1 Tab/Cap	DIABEND MR 60	10 Tab	1.17/1 Tab	Rupee One Paise Seventeen Only	L-2
168	UNICURE INDIA LTD	576b	Gliclazide MR Tab/Cap-Each Modified Release Tab/Cap to contain: Gliclazide 60mg.	1 Tab/Cap	Gliclazide Modified Release Tablets 60 mg	10 Tab	1.19/1 Tab	Rupee One Paise Nineteen Only	L-3
168	Aculife Healthcare Pvt. Ltd.	603b	Intravenous Lipid Soln 20%- Each 100ml to contain: Fat Emulsion Containing Fractionated Soyabean Oil 20gm, Fractionated Egg Phospholipids 1.2gm, Glycerol 2.2gm.,250ml	1ml	Liposteril 20%	250ml Bottle	2.80/1ml	Rupees Two Paise Eighty Only	L-1

END OF RATE CONTRACT

ESIC